Skip to main content
. 2018 Jun 8;36(9):1380–1392. doi: 10.1002/stem.2844

Figure 5.

Figure 5

DMOG reduces the formation of a cartilage‐like ECM. (A–H): Collagen Type X (A–D) and II (E–H) immunofluorescence staining at day 21 of chondrogenesis (n = 3). Scale bar = 400 μm. Brightness and contrast were adjusted to an equal degree between all conditions. (I–L): Alcian blue staining for GAGs with hematoxylin counterstain at day 21 of chondrogenesis (n = 3). Scale bar = 400 μm. (M, N): Quantification of Collagen Type II immunofluorescence (M) and glycosaminoglycans (N) at day 21 of chondrogenesis (n = 4) without and with normalization to DAPI‐immunofluorescence/double‐stranded DNA. Values are fold change compared with the no‐treatment control represented by the horizontal dotted line. Solid colored lines represent means for each condition. *p < .05 compared with 20%O2. Abbreviations: CoCl2, cobalt chloride; DFX, desferrioxamine, DMOG, dimethyloxalylglycine; GAGs, glycosaminoglycans.